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Abstract
Current genome-wide association studies (GWAS) are moving towards the use of large cohorts of primary cell lines to study
a disease of interest and to assign biological relevance to the genetic signals identified. Here, we use a panel of human
osteoblasts (HObs) to carry out a transcriptomic survey, similar to recent studies in lymphoblastoid cell lines (LCLs). The
distinct nature of HObs and LCLs is reflected by the preferential grouping of cell type–specific genes within biologically and
functionally relevant pathways unique to each tissue type. We performed cis-association analysis with SNP genotypes to
identify genetic variations of transcript isoforms, and our analysis indicates that differential expression of transcript isoforms
in HObs is also partly controlled by cis-regulatory genetic variants. These isoforms are regulated by genetic variants in both
a tissue-specific and tissue-independent fashion, and these associations have been confirmed by RT–PCR validation. Our
study suggests that multiple transcript isoforms are often present in both tissues and that genetic control may affect the
relative expression of one isoform to another, rather than having an all-or-none effect. Examination of the top SNPs from a
GWAS of bone mineral density show overlap with probeset associations observed in this study. The top hit corresponding
to the FAM118A gene was tested for association studies in two additional clinical studies, revealing a novel transcript
isoform variant. Our approach to examining transcriptome variation in multiple tissue types is useful for detecting the
proportion of genetic variation common to different cell types and for the identification of cell-specific isoform variants that
may be functionally relevant, an important follow-up step for GWAS.
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Introduction
Human genetic variation plays a key role in shaping phenotypic
diversity amongst individuals, where the underlying mechanisms
may include polymorphisms that alter protein coding sequences or
changes in regulatory sequences that affect the function of a gene
or related gene networks. These alterations can affect heritable
quantitative traits as well as susceptibility to common complex
diseases [1]. Many early genome-wide association studies (GWAS)
linking gene expression to genetic variation utilized lymphoblas-
toid cell lines (LCLs) and conclusively demonstrated the
widespread impact of standing variation in governing-gene
expression and population variability on expression traits [2,3,4].
These studies benefitted from the dense-genotyping information
that is publicly available for the HapMap LCL samples [5].
Recently, using a subset (HapMap CEU) of these same LCLs, we
demonstrated that genetic variants can be associated with
expression changes at the exonic level and lead to alternatively
spliced variants [6]. In a broader context, the expression of
different transcript isoforms within individuals is partly under
genetic control. Such isoform differences encompass inclusion or
exclusion of cassette exons which may encode for important
functional domains or structural motifs, or the alterations may be
regulatory in nature with changes in the 59 or 39 untranslated
regions leading to differences in translation initiation, mRNA
stability, or mRNA localization.
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Although the use of LCLs has generated tremendous amounts
of useful information for genetic association and population
genomics studies, this cell type does pose certain limitations. LCLs
are immortalized cell lines and therefore may include potential
artificial phenotypic and epigenetic alterations induced by
immortalization and prolonged cell culture [7,8,9]. Even when
LCLs are derived from a disease cohort of interest [10], they may
not be truly representative of the regulatory landscape in the
affected tissue of interest. Despite some of the caveats of LCLs,
they have proved to be a valuable model system to establish
patterns of heritable gene expression. Recently, the focus has
expanded to examine genetic variation in other tissue types that
may be more relevant to the disease or phenotype being studied,
although large cohorts of all of these cell types are not always
readily available. For example, genetic control of splicing in
humans was examined using cortical brain tissue samples and
peripheral blood mononucleated cell (PBMC) samples [11] but so
far no studies on primary cultured cells have been performed.
In this study, we use cultured human osteoblasts (HObs), which
are key players in the bone remodeling process including bone
resorption and producton of bone matrix [12]. Osteoblasts are
relevant to the study of osteoporosis, a skeletal disorder
characterized by imbalances in the remodeling process, leading
to compromised or weakened bone strength. Osteoblasts can be
extracted from bone fragments, which are readily available from
institutions performing routine hip replacement surgeries, making
them a practical and useful resource for studying bone-related
functions [13,14,15]. Using a similar strategy employed for the
LCLs [6], we use the Affymetrix Human Exon Array for a
population genomic examination of the human osteoblast
transcriptome. Genotype information for our HOb panel was
obtained using the Illumina Hap550K chip and used in a genome-
wide association analysis with the exon expression data to identify
transcript isoform variations showing genetic association to SNPs,
and relate these isoform variants to potentially important
biological roles in the bone remodeling process. This data was
also compared with our previous results for the LCLs in order to
detect common transcript isoform differences as well as tissue-
specific variations. A similar approach was recently used for a
comparison of brain and PBMCs [11] and the findings in that
study will be discussed in the context of our results. Finally, our
results were compared to the top SNP associations identified from
a GWAS of bone mineral density [16,17], which suggests that a
significant proportion of hits may be involved in expression of
alternative splice isoforms. We selected one example (FAM118A)
from the overlapping hits for follow-up fine-mapping studies,
which revealed a novel transcript isoform with potential functional
importance in bone biology.
Results
Quality control of microarray data and population
stratification
We investigated genetic variation on exon expression levels in a
panel of 58 unrelated human osteoblast (HOb) samples of Swedish
origin using the Affymetrix Human Exon 1.0 ST array (gender
and year of birth detailed in Table S1). Expression values at the
exon and gene levels were generated using the Robust Multichip
Average (RMA) algorithm [18,19]. Principal component analysis
(PCA) was performed on the exon and gene level expression scores
and did not identify any outliers for exclusion from the analysis
(Figure S1). Genetic stratification was analyzed by EIGENSTRAT
[20] and no indication of major population structure was seen in
the osteoblast samples (P = 0.172446, Tracy-Widom test for first
Eigen axis).
Overall gene expression in osteoblasts and lymphoblasts
A mean expression score across 17793 genes was calculated and
used as an arbitrary cutoff for presence/absence calls in a
particular cell type. For HObs and LCLs, mean RMA expression
scores of 6.193 and 6.196 were calculated, corresponding to 9227
(51.9%) and 9297 (52.3%) genes expressed, respectively in the two
tissues. Although this mean expression value cutoff is conservative
and may miss genes that are expressed at very low levels or just
above array background, this cutoff was chosen so that we could
compare a highly confident set of expressed genes from the two
cell lines. From these two lists, 7733 (43.5% of the total) genes were
expressed in common between the two cell types. These results are
in line with a recent study using a similar set of samples on the
Affymetrix Human Genome U133 Plus 2.0 Array [21].
We performed a network analysis using the Ingenuity Pathways
Analysis (IPA) system on the sets of genes expressed uniquely in
each cell type. The most significant or overrepresented networks
corresponded to biological function(s) normally associated with
that particular tissue (Table S4). The Wnt/b-catenin signaling,
BMP (bone morphogenetic protein) signaling and IGF-1 signaling
pathways were among the most significant HOb networks; these
are known to be important in the bone remodeling process
[22,23,24]. Conversely for the LCL-specific genes, the top
canonical pathways included B-cell receptor signaling, NF-kB
signaling, and natural killer cell signaling which are involved in the
immune response system and are typically functions associated
with lymphocytic cell types.
We also performed a network analysis for the set of 7733 shared
HOb and LCL expressed genes (Table S3), and identified general
cellular functions required for cell survival such as protein
ubiquitination, glucocorticoid receptor signaling, PI3/AKT sig-
naling, oxidative phosphorylation, and purine/pyrimidine metab-
Author Summary
The transcriptome of any given cell type is a complex
program of controlled gene expression underlying its
biological function. An additional layer of molecular
complexity involving individual genetic variation can
modulate the transcriptome within the same tissue type,
conferring potential phenotypic differences between
individuals at the cellular level. This study highlights
common and unique aspects of the transcriptome
between the well-characterized lymphoblastoid cell lines
from the International HapMap Project and those of a
cultured primary cell type, human osteoblasts. We observe
that inter-individual genetic variation can regulate tran-
script isoform expression in tissue-specific and tissue-
independent manners, indicating that genetic differences
among individuals can alter the transcriptome in one or
more tissues, ultimately leading to altered biological
functions within the lymphoblasts and/or osteoblasts.
Pursuant to this, genome wide association studies on
bone mineral density (BMD) have identified a number of
significant loci and polymorphisms highly linked to the
BMD quantitative phenotype. A small proportion of these
polymorphisms overlap with our highly significant SNPs
regulating the osteoblast transcriptome, revealing a
potential molecular basis for this phenotype at the
transcriptional level. This study highlights the importance
of examining the differing transcriptomes and cis-regula-
tory mechanisms governing the biological and functional
roles of varied tissue types.
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olism. When this list is further subdivided into subsets of genes that
are upregulated in either HObs or LCLs (.36fold change mean
expression) (Table S2), we again observe enrichment of biological
networks that are intuitively predicted to be associated with that
particular cell type (Table S5). Genes that are upregulated in
HObs (n= 233) are preferentially found in integrin signaling, actin
cytoskeletal signaling, and IGF-1 signaling pathways. Conversely,
LCL-upregulated genes (n = 493) are found within antigen
presentation, NF-kB signaling, and interferon signaling pathways.
These results indicate that overall, there is a large overlap in genes
expressed in the two cell types, as well as the associated functional
pathways. However, by concentrating on the much smaller subset
of cell type-specific genes, the networks analysis preferentially
identifies biologically and functionally relevant pathways that are
unique to both osteoblasts and lymphoblasts.
Comparison of effects of common genetic variation on
transcript isoforms between tissues
Before carrying out association analyses of meta-probeset-SNP
and probeset-SNP associations, we note that there will be a
decrease in the significance levels from the linear regression
statistic for the HOb samples as compared to our previous work on
LCLs. This is due to the fact that although similar sample sizes in
LCLs and HObs (57 versus 58) were used, the expression values
for LCLs are derived from the mean of three replicate samples
whereas only a single HOb replicate is used. The increased
statistical power generated from the use of triplicate samples will
be reflected in lower variance between different samples and
accordingly, a more significant P-value for true associations. This
will be an important consideration when comparing associations
between the two sample sets and looking at overlapping or unique
genetic associations. Gender, age, batch effects, and the first eigen
vector (from Eigenstrat analysis) were used as covariates in the
regression analysis to account for any possible stratification.
We first examined the top 100 associations at the gene level in
HObs and looked at the overlap of these genetic associations in
LCLs, with the criteria that the gene must be expressed in both
tissue types. Out of the top 100 unique genes and the top SNP
association for each gene (P-values range from 7.298e-11 to
1.327e-04) in osteoblasts, we observed a 21% overlap in
associations in lymphoblasts (nominal P-value,0.05). Multiple
correction was also performed on the corresponding P-values for
the same gene-SNP in lymphoblasts; 18% and 13% of associations
were significant at 0.05 and 0.01 FDR levels, respectively. FDR
was performed in consecutive 100 gene blocks in decreasing order
of significance in HObs, with a resultant decreasing number of
significant associations at both the 0.05 and 0.01 FDR levels in
lymphoblasts (Figure S2A). This indicates an enrichment of
common top associations between HObs and LCLs as well as a
non-random nature of these top P-values. Conversely, when the
top 100 gene-SNP associations in LCLs (P-values range from
3.347e-22 to 5.48e-06) were compared to HObs at a P,0.05
cutoff, 47% of associations were shared between the two cell types,
and 37% and 23% were significant at 0.05 and 0.01 FDR levels,
respectively, along with a similar decrease in shared associations
for decreasing levels of significance in LCLs (Figure S2B).
A similar analysis was performed at the exon level, with the one
major criterion to enrich for alternative splicing (AS) changes
rather than whole gene expression changes. We limited ourselves
to transcripts where the corresponding transcript (meta-probeset)
did not show association to the same SNP showing association
with the probeset. The top 100 probesets and the most significant
SNP association for each probeset (P-values range from 4.93e-14
to 1.338e-5) in HObs showed 52% overlap of associations in LCLs
(P,0.05) and 46% and 40% significant associations at 0.05 and
0.01 FDR levels, respectively. Conversely, the top 100 probesets in
LCLs (P-values range= 6.247e-21 to 2.776e-7) showed 60%
common associations in HObs (P,0.05) and 53% and 37%
significant associations at 0.05 and 0.01 FDR levels, respectively.
Similar to the analysis for the meta-probesets, FDR analysis on
blocks of decreasing P-value significance for probesets in one tissue
show a corresponding decreasing enrichment of significant
associations in the other tissue (Figure S2C, S2D).
Clearly, for the top associations there are shared hits between
HObs and LCLs at both the probeset and meta-probeset levels,
suggesting that there is a common genetic control of transcript
isoform expression that is independent of the types of tissues
examined in this study.
In our previous study, we validated 25 transcript isoforms
showing strong genetic association to SNPs in LCLs (P= 2.81e-37
to 3.53e-08) [6], and we sought to determine the level of
replication in osteoblasts (Table 1). Validation was carried out
by standard and quantitative real time RT-PCR on a panel of
individuals with one or the other allele of the associated SNP in
question. For two of the genes (TAP2 and C17orf57), we were
unable to detect any PCR product in HObs. Of the remaining 23
genes tested, 18 (78%) showed the same two allele-specific isoforms
that were previously observed in LCLs in the same direction of
effect, indicating that the AS event is also correlated with SNP
genotype in this cell type. This indicates that for the majority of
these cases, expression of allele-specific transcript isoforms occurs
in a tissue-independent manner for the two tissue types that were
tested, providing further support for a common transcriptional
regulatory mechanism for these genes in HObs and LCLs.
Tissue-specific genetic variation of transcript isoforms
Next, we examined the set of genes expressed in both cell types
(n = 7733) for examples of tissue-specific genetic associations, i.e.
allele-specific expression of isoform variants in HObs but not in
LCLs, to identify any unique transcript isoforms with potentially
important biological functions in osteoblasts. One criterion was
that the gene itself was not significantly associated (P.0.05) with
the same SNP as the probeset, in order to limit the number of
probesets within the gene showing allele-specific expression
differences and also to reduce the complexity of interpreting the
predicted isoform changes. The top 100 ranked unique probesets
(P,1.338e-5) in HObs corresponded to 84 unique meta-probesets.
To identify allelicly expressed probesets specific to HObs but not
to LCLs, the association analysis for the same probeset and SNP in
LCLs was performed and any probeset showing a nominal P-
value,0.05 in LCLs was discarded. This resulted in 48 probesets
from 47 unique meta-probesets showing significant HOb-specific
associations. Conversely, we also selected the top 100 unique
probesets (P,2.776e-7) in LCLs corresponding to 82 meta-
probesets. These top ranked probesets in LCLs were then filtered
to exclude for significance in HObs, resulting in 40 probesets from
34 meta-probesets that showed LCL-specific genetic association.
These results indicate that nearly half of the top 100 ranking hits in
HObs are not significant (nominal P-value,0.05) in LCLs, and
this frequency is similar when comparing the top LCL associations
to the HObs, suggesting that we can identify tissue-specific in
addition to tissue-independent isoform variations from the
microarray data.
We selected 20 examples of tissue-specific isoforms showing
large effect sizes in one tissue but not the other, for validation by
standard RT-PCR and electrophoresis, however we only observed
the similar expression patterns in both tissues, indicating a lack of
tissue-specificity. Since this is a qualitative-based detection
Tissue-Specific Transcript Isoform Variation
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method, we used the more sensitive quantitative real time RT-
PCR to detect possible cases of smaller expression differences
between isoforms for another set of candidates. We looked at an
additional seven HOb-specific candidate isoforms events, and in
four cases (TIPARP, ESPNL, P4HA2, and EPN3) we observed
allele-specific expression differences in osteoblasts but not in
lymphoblasts, using cutoffs of significance and non-significance in
these two tissues respectively, as described in the Materials and
Methods. P4HA2 is a prolyl 4-hydroxylase which is a key enzyme
in collagen synthesis, and ESPNL and EPN3 are part of the espin
gene family that are involved in the production of the extracellular
matrix. The identification of transcript isoform variants in one
tissue but not the other indicates that there are some tissue-specific
factors at play, either in promoting transcription of the SNP-
associated isoform or suppressing the genetic effect of the
polymorphism. However, our low validation rate of the micro-
array results suggests that cis variants controlling expression of
tissue-specific isoforms may not contribute to a large proportion of
inter-tissue variability.
The set of genes uniquely expressed in HObs showing genetic
associations were examined for any enrichment in biologically
relevant functions. While this biases the analysis towards genes
having a potentially important function in osteoblasts, the aim was
to assess whether certain genes or entire pathways are preferentially
under the influence of genetic control. The 1000 highest ranked
unique probesets showing SNP association were examined using
IPA and the top canonical pathways identified (Table S6) included
the Wnt/b-catenin signaling system (P= 2.97e-3) and IGF-1
signalling pathways (P= 2.63e-2) important in the bone remodeling
process [22,23,24]. Conversely, examining the top 1000 ranked
probesets in lymphoblasts revealed the B cell receptor signaling
(P= 1.32e-4), iCOS-iCOSL Signaling in T Helper Cells (P= 1.45e-
3), FccRIIB Signaling in B Lymphocytes (P= 1.88e-3), BRCA1 in
DNA damage response (P= 4.02e-3), and Fc Epsilon RI signaling
(p= 1.09e-2) among the top LCL networks associated with potential
isoform variation.
Comparison of probeset associations with known bone-
related GWAS loci
A recent GWAS [16,17] with 300K SNPs identified sequence
variants in nine genomic regions significantly associated with bone
mineral density (BMD), which influences the risk of osteoporosis.
We examined the top 100 SNPs from quantitative trait analyses of
hip BMD [17], of which 91 were tested in our analysis, and looked
at the relative levels of replication for these polymorphisms in our
probeset association results for potential transcript isoform
variations linked to the same SNPs or to a SNP in close LD
(defined as D’ = 1, MAF.0.10 and located 650 kb flanking the
Table 1. Replication of validated LCL probesets in Hobs.
Gene Probeset ID SNP (LCL) P-value (LCL) SNP (HOb) P-value (HOb) Replicated in HObs?
Cep192 3779862 rs482360 3.71E-19 rs570505 4.22E-03 No
ZNF83 3869658 rs1012531 2.72E-10 rs1012531 5.39E-02 Yes
C17orf57 3724617 rs3760372 5.54E-12 rs3760372 4.29E-01 No
CAST 2821249 rs7724759 7.17E-16 rs13362120 4.73E-13 Yes
CD46 2377476 rs4844390 1.06E-14 rs2761437 6.02E-02 Yes
FLJ10241 3863093 rs1043413 9.38E-11 rs3810174 1.15E-03 Yes
LRAP 2821389 rs2255546 8.37E-22 rs2161657 8.39E-01 Yes
POMZP3 3057764 rs2005354 3.77E-22 rs17718122 1.70E-10 No
ULK4 2670619 rs1717020 5.99E-11 rs9852303 1.45E-05 Yes
PARP2 3527423 rs2297616 2.81E-37 rs3093942 4.94E-07 Yes
ATPIF1 2327383 rs2481974 4.26E-11 rs8559 1.70E-01 No
MRPL43 3303658 rs12241232 1.24E-11 rs3740487 2.44E-05 Yes
DKFZp451M2119 2588913 rs10930785 1.93E-28 rs10930785 1.56E-09 Yes
RNH1 3358076 rs11821392 4.34E-15 rs12420868 4.88E-01 Yes
SNX11 3725089 rs7224014 4.20E-09 rs2240122 1.47E-01 No
USMG5 3304753 rs7911488 2.66E-24 rs1163073 6.45E-11 Yes
SEP15 2421300 rs1407131 7.57E-13 rs17452535 1.01E-02 Yes
SLC35B3 2941033 rs3799255 2.12E-10 rs3799255 1.30E-02 Yes
DERP6 3708382 rs2521985 2.55E-13 rs222851 6.18E-04 Yes
ARTS-1 2868133 rs7705827 6.09E-19 rs1862609 3.98E-06 Yes
TAP2 2950168 rs3763355 1.98E-13 rs241448 4.48E-01 No
IRF5 3023264 rs6969930 8.27E-22 rs10239340 8.94E-01 Yes
PPIL2 3938301 rs5999098 1.46E-12 rs5754727 1.54E-02 Yes
PTER 3236819 rs1055340 5.25E-18 rs7909832 6.24E-13 No
WARS2 2430765 rs1325933 3.53E-08 rs1325933 6.38E-01 Yes
List of candidate probesets previously validated in Kwan et al (2008) by qualitative or quantitative RT–PCR. The gene name and the significant probeset are indicated
along with the SNP in LCLs and P-value from the linear regression analysis. Since the HOb panel was only genotyped using the Hap550K chip, we selected the SNP in
HOBs that was in highest LD with the original SNP associated in LCLs. The last column indicates whether the allele-specific isoform changes were originally validated in
LCLs was replicated in the osteoblast samples.
doi:10.1371/journal.pgen.1000608.t001
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GWAS SNP). In our HOb probeset associations, we observed 15
out of 91 (16%) BMD GWAS SNPs showing association at a
Bonferroni cutoff of 5.49e-04 (0.05/91) (Table S9). This indicates
that of the top polymorphisms identified from GWAS, a small
proportion of them may be involved in the regulation of
alternatively spliced transcripts that play a role in modulating
the BMD phenotype. These 100 SNPs are represented by 63 loci,
and of these 63 loci implicated in BMD variation, 13 loci (21%)
may be attributable to cis-regulatory variation.
Validation of a novel bone-related GWAS locus: FAM118A
Based on the comparison of probeset associations with known
bone-related GWAS loci, we examined the top hit (rs136564,
P=4.88E-07, Table S9) in greater detail to determine the nature of a
possible isoform variant. The probeset (3948557, chr22:44,102,552-
44,102,577) maps to exon 5 in the FAM118A gene (Figure 1A)
encoding a hypothetical protein (LOC55007) with so far unknown
function. We fine-mapped (chr22:44,083,527–44,118,573) and re-
sequenced (chr22:44,097,900–44,104,182) the candidate region and
expanded the association analysis of transcript isoform variations by
including non-core probesets (chr22:44,083,527–44,118,573)
(Figure 1B). The non-core probesets are defined as the less confident
probesets on the Exon Array corresponding mainly to computation-
ally predicted exons rather than experimentally verified RefSeq
exons. Using the information from all the FAM118A probesets
(Figure 1B), we detected expression of additional probesets between
exons 5 and 6 that differ from the RefSeq variants (NM_001104595
and NM_017911) (Figure 1C) suggesting a potentially new transcript
isoform variant, previously unsupported by ESTs. We confirmed the
novel transcript variant by sequencing RT-PCR and 59 RACE
Figure 1. Validation of the genetic effect of FAM118A probeset expression. (A) RefSeq transcript variants, NM_001104595 and NM_017911,
for the FAM118A gene and (B) all corresponding probesets included on the Affymetrix Human 1.0 ST Exon array. RMA normalized expression scores
for all probesets, as shown by vertical bars (C), indicate expression of additional probesets that differ from the RefSeq variants. Validation studies by
RT–PCR and 59 RACE confirmed expression of probesets marked in red (A) and represent a novel FAM118A transcript variant (D). Fine-mapped SNPs
(E) show highly significant associations with expression of probeset 3948567 (marked as green throughout the figure) and P-values represented as –
log10(P-value) are shown as vertical bars (F). Dashed line indicates cutoff P = 10e-4.
doi:10.1371/journal.pgen.1000608.g001
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amplified fragments (Figure 1D) from eight individuals (four samples
from each homozygous genotype group of the top SNPs). The
identified transcript variant differs from the RefSeq variants at the
59UTR, exon 5 and at the 39UTR, respectively (Figure 1D). We
observed highly significant associations of fine-mapped SNPs
(Figure 1E) (see Table S10 for full list of SNP-probeset associations)
in the FAM118A gene with expression of probesets within the 46;1F).
Notably, we did not observe associations of probesets uniquely
expressed in the RefSeq variants (3948549, 3948585, data not
shown). We then performed a similar association analysis using our
LCL CEU samples but extended the analysis by including all
HapMap SNPs in the region of interest (i.e. 6250 kb flanking the
FAM118A transcript) and found a similar, highly significant
association of expressed, transcript-specific probesets and SNPs
within the FAM118A gene (Figure S3). However, the strong LD
among the common SNPs associated with the probeset expression
did not allow delineation of the causal variant(s). We confirmed the
significance and direction of the association analysis of the FAM118A
SNPs for both HObs and LCLs by quantitative real-time RT-PCR
using two different primer pairs (Figure 2). As shown in Figure S4, the
tissue independent association of probeset expression seen in HOb
samples was further confirmed in a second LCL population, the
Yoruba (YRI) population [5,25], as well as in cortical brain tissue
samples and peripheral peripheral blood mononuclear cells (PBMCs)
from the SNPExpress Database [11].
To validate the original finding in the GWAS linking genetic
variants in the FAM118A locus with differences in bone
phenotype, we performed a candidate gene association study of
Figure 2. Validation of microarray association using real-time RT–PCR. The effect of SNPs on FAM118A probeset expression was validated by
quantitative real-time PCR in HObs (n = 31, lower panel) and LCLs (n = 8, upper panel). The rs104664 and rs738177 represent the top significant SNPs
associated with probeset expression in the microarray analysis in HObs and LCLs, respectively. Primers were designed to amplify probesets 3948567
(left panel) and 3948555/3948556 (right panel), respectively. Relative expressions were calculated using the comparative CT method using 18S as a
housekeeping gene and associations were assessed using a linear regression model. The P-values and R2 of the linear regression statistic are shown
within each boxplot.
doi:10.1371/journal.pgen.1000608.g002
Tissue-Specific Transcript Isoform Variation
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BMD and our top candidate SNP (rs104664, see Figure 1) in a
cohort of randomly selected elderly Swedish men from the MrOs
Sweden study. In total, 2880 individuals were analyzed with
genotype frequencies of: CC=0.02, CT=0.26 and TT=0.72
(MAF C=0.15, H-W P=0.31). The candidate SNP was
associated with lumbar spine BMD (P= 0.0065, n = 2856) but
not with femoral neck BMD (P=0.61, n= 2778). Lumbar spine
BMD decreased 0.067 g/cm2 in the minor C allele homozygous
group compared to the TT group. We pursued replication of the
association of the rs104664 SNP with BMD in 2100 elderly men
from the population-based Rotterdam study with genotype
frequencies of: CC=0.02, CT=0.20, and TT=0.78 (MAF
C=0.12, H-W P=0.02). We were however not able to replicate
the previous findings in the Rotterdam study either with lumbar
spine (P= 0.35) or femoral neck (P= 0.28) BMD.
Discussion
The study of transcriptomic effects of genetic variation is shifting
from the use of well-characterized lymphoblastoid cell lines (LCLs)
to primary cell lines that are more biologically relevant to a
particular disease or phenotype of interest. Human osteoblasts
(HOb) are the primary cell type responsible for the bone
remodeling process and alterations in this pathway can lead to
disorders such as osteoporosis, therefore HObs represent a very
good model system for the study of bone biology and bone-related
diseases in general. Using a strategy that we previously employed
for the study of genetic variation in LCLs, we assessed SNP
association in the HOb transcriptome to assess the nature of
common and unique cis-variants controlling transcript isoform
expression in the two cell types.
Gene ontology analyses of the top associations from each tissue
also revealed certain networks that were enriched in these isoform
variants. Genes that are expressed in multiple cell types are
predicted to share many common biological functions and
pathways responsible for general cell growth and survival. In fact,
genes whose expression levels are very similar in both HObs and
LCLs are enriched in pathways that are important in cellular
growth and maintenance such as inositol phosphate metabolism,
N-glycan synthesis, purine metabolism, and pyrimidine metabo-
lism. Functions that are required for general cell survival across
multiple tissue types are expected to be constitutively on and
therefore should require less regulatory mechanisms and modules
controlling its expression as compared to tissue-specific genes
whose expression needs to be temporally and spatially controlled
by a set of more complex regulatory sequences and events. The
top osteoblast specific isoform variants preferentially mapped to
biological networks involved in cell and tissue development,
including tight junction signaling and keratan sulfate biosynthesis
pathways suggesting more complex regulation of these functions.
A large set of genes is expressed in both HObs and LCLs,
producing a vast array of transcript isoforms that are affected in
both cell types by a common regulatory SNP and tissue-
independent fashion. However, certain isoform variations are
tissue-specific despite the presence of the same genetic background
or haplotype in other cell types, suggesting that other mechanisms,
such as tissue-specific transcription factors, splicing factors, or
small non-coding RNAs that are present in only one of the cell
types additionally regulates transcription. For example, brain
tissue expresses a neuronal-specific splicing factor, Nova, which
increases the levels of alternative splicing in neuronal versus
immune tissues, as shown from recent studies using Nova knockout
mice [26]. Despite the presence of identical regulatory sequences
in neuronal and immune tissues and in both wild-type and
knockout mice, only these sequences in brain are recognized by
Nova due to its restricted expression pattern, resulting in the
generation of multiple brain-specific isoforms.
Despite the limited number of validated examples, osteoblast-
specific transcript isoforms are present and indicates that
expression of certain alternatively spliced variants in bone tissue
are controlled by different regulatory SNPs and vary between
individuals and/or populations, with potentially important
biological functions. The future use of more sensitive quantitative
methods may identify smaller, subtler differences in isoform
expression that can alter an important biological pathway, leading
to a cascade of downstream functional consequences. A plausible
explanation is that the combined effects of many such genetic
variations are probably necessary for deviations in the normal
function of complex diseases such as osteoporosis.
One factor compounding an accurate statistical comparison of
genetic variation between the different cell types were the numbers
of samples used: 58 HObs (n= 1) versus 57 LCLs (n= 3). The
triplicate LCLs decreases variability between samples compared to
the single replicate HOB samples; therefore linear regression with
the noisier HOb data set will result in lower significance in P-
values for the regression statistic. The small sample sizes used here
for each tissue type is also limiting in the power to detect very large
size effects, even for very significant genetic associations, and is a
caveat to the identification and validation of many but the top
associations, but at the benefit of reduced cost for the experiment.
Another important factor contributing to the relatively little
overlap is due to expression level differences between tissues.
Generally, genes with a strong genetic expression effect and with
high expression in LCLs will be highly ranked by P-value
significance from the linear regression analyses. However, if the
expression signal is much lower and therefore signal strength is
noisier in HObs, despite an equally strong genetic effect, the linear
regression statistic produces a lower P-value and hence, a lower
ranking on our list. A comparison of the top 100 significance-
ranked probesets from similarly expressed genes versus genes with
at least 3-fold expression differences between the two tissues
showed a level of replication that was nearly two-fold higher in the
set of genes with comparable expression (data not shown). This
explains the low level of replication between the tissues from the
microarray data analyses and suggests that microarray results may
in fact underestimate the extent of genetic variation common to
both tissues. Since gene expression is also highly variable from
tissue to tissue, the sensitivity of microarray studies for any given
subset of genes will also vary for any given tissue, compounding the
analysis of common variation. These differences in dynamic range
between the methods used may explain some of the contrasting
results for the levels of replication between LCLs and HObs that
we observed using microarrays or RT-PCR validation. The
discrepancy between associations based on the microarray results
and the RT-PCR validation studies can also be explained by the
false positive rates associated with the analysis of microarray data.
If one assumes a liberal false positive rate of 50% from one tissue
type, combining the analysis with potential hits from a 2nd tissue
type with an equal false positive rate to look for tissue-specific hits,
one can expect a maximum of 25% true positives.
Our results were compared with a similar study examining
tissue-specific genetic control of splicing in brain tissues and
PBMCs. Using very stringent cutoffs, 23 and 80 high confidence
associations at the meta-probeset and probeset level, respectively
were identified. However, fewer than half the associations were
common to both tissues, reflecting strong evidence for distinctive
tissue-specific genetic control of transcript isoform expression. This
corroborates the suggestion of tissue-specificity of genetic control
Tissue-Specific Transcript Isoform Variation
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from our own SNP-association results in HObs and LCLs. One
contrasting difference was that our rate of validation did not
strongly support the microarray data as we would have expected.
Three examples of tissue-independent and tissue-specific genetic
control of splicing (ULK4, SLC12A7, KLHL24) were shown,
however these were not the most significant candidates from the
study, nor was any information provided on validation rates.
Without rigorous validation of more candidate splicing events
from both studies, we still cannot assess the prevalence of genetic
control of tissue-specific transcript isoforms. Moreover, the
assessment of tissue-specific transcript isoforms in samples derived
from different individuals reported here and by others [11] is a
limitation since small differences in allele frequencies can bias the
comparison. It is only through examination of multiple tissues
derived from the same individual that we can obtain the full
spectrum of tissue-specific genetic variation of transcript isoforms.
Comparison of our exon-level eQTL data with known SNPs
from a GWAS of bone mineral density indicates that ,20% of the
top associated SNPs from the quantitative trait study may be
linked to transcript isoform variation. Follow up of one of the top
hits (FAM118A) from our association data that overlaps with the
GWAS hits revealed a novel isoform variant associated with three
SNPs obtained from fine-mapping the gene region. Further
analysis in different tissues and populations confirmed the strong
association of SNPs with expression of the novel transcript variant.
The osteoblast donors were not ascertained for osteoporosis or
BMD to allow testing directly the transcriptomic association at the
population level. However, the genetic contribution to trait
variance of cell-based traits are several-fold higher as compared
to complex traits assessed in clinical cohorts, so even if phenotypes
were available for the osteoblast donors, our power would have
been low in detecting small differences. Instead, we tested the top
hit in FAM118A in an independent Swedish cohort of .3000 men
where we found the SNP to be associated with the BMD
phenotype. Individuals homozygous for the minor C allele, earlier
shown to be associated with increased expression of the novel
isoform, had lower BMD indicating a negative effect of the
expression of the gene on bone phenotypes. The failure to
replicate the association in the second cohort is probably due to
the lack of power needed to detect such small genetic effects
(B = 0.63), as shown in a post-hoc power analysis using a=0.05 and
an effect size explaining 0.005 of the additive QTL variance in
BMD. Other factors like population specificity due to differences
in LD, differences in phenotype assessment, selection of individuals
and/or genotyping errors may also play a role. We cannot rule out
that some of the discrepancy in association between the two
cohorts may be due to a false positive result, however this will
require further extensive validation in both cohorts.
There is an increasing trend amongst the scientific community
towards the use of primary tissues from normal and disease-
affected patients for the association and fine mapping of genetic
variants with quantifiable phenotypic traits. These studies are
being carried out in increasingly large cohort samples that are
more costly for the collection, processing, and microarray analyses
of these samples. Despite the limitations of using the HapMap
LCLs as described earlier, they do possess the advantage of
availability and wealth of public data derived from these samples.
Our data comparing LCLs and HObs, in particular the RT-PCR
replication of many of our LCL isoform variants in osteoblasts,
suggests that although we can identify HOb-specific transcript
variants, a large proportion of variation for genes expressed in
both cell types is common between them. Studying transcriptome
variation across multiple tissue types, and in particular the subsets
of genes that are commonly expressed in all tissues, will allow us to
determine the proportion of genetic variation that is common
between different cell types. However, examining the sets of genes
uniquely expressed in a single cell type will allow for the
identification of cell-specific isoform variants that may be
functionally important. Only through an examination of as many
tissues as possible can we obtain the full spectrum of genetic
variation in the human transcriptome. Using these large
expression and association datasets in conjunction with the
expanding list of polymorphisms identified from GWAS may aid
in the fine mapping and delineation of the molecular basis behind
various diseases and quantitative phenotypes.
Materials and Methods
Bone cell culture for whole genome expression profiling
Human trabecular bone from the proximal femoral shaft was
collected from 60 donors undergoing total hip replacement. The
bone samples from each donor were thoroughly washed, minced
and cultured in medium containing a-MEM (Sigma-Aldrich,
Oakville, Canada) supplemented with 2 mmol/l L-Glutamine,
100 U/mL penicillin, 100 mg/mL streptomycin (Invitrogen,
Burlington, Canada), and 10% fetal bovine serum (Sigma-Aldrich,
Oakville, Canada) at 37uC with 5% CO2 until confluence was
reached. At 70–80% confluence, the cells were harvested and
stored in 270uC until RNA and DNA extraction.
RNA and DNA extraction
RNA was isolated using the commercially available TRIZOL
reagent (Invitrogen, Burlington, Canada) protocol and treated
with DNaseI (Ambion Inc., Austin, TX, USA) for 40 min at 37uC
and further extracted with phenol/chloroform (Invitrogen,
Burlington, Canada). The RNA was further purified using the
RNeasyMinElute Cleanup kit (Qiagen, Mississauga, Canada).
High RNA quality was confirmed for all samples using the Agilent
2100 BioAnalyzer (Agilent technologies, Palo Alto, CA, USA) and
the concentrations were determined using the Nanodrop ND-1000
(NanoDrop Technologies, Wilmington, DE, USA). DNA was
extracted from the cell lysates using the GenElute DNA Miniprep
Kit (Sigma-Aldrich, Oakville, Canada) according to the protocol
provided by the manufacturer.
Microarray analysis
Expression profiling was performed for each sample with the
Affymetrix Human 1.0 ST Exon array (Affymetrix, Santa Clara,
CA). One microgram of RNA was reverse transcribed into cDNA,
and in vitro transcription was performed to generate biotin-labeled
cRNA for subsequent hybridization. Hybridized target cRNA was
then stained with streptavidin-phycoerythrin, and the arrays were
scanned with a GeneArray Scanner at an excitation wavelength of
488 nm. The microarray data have been deposited in the Gene
Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo, acces-
sion no. GSE15252).
Robust multichip average (RMA) adjustments
All probeset and meta-probeset expression values from the
human primary bone samples were generated using the robust
multichip average (RMA) algorithm from the Affymetrix Power
Tools software package. To prevent the introduction of batch
effect bias between the osteoblast and lymphoblast datasets, the
raw microarray data from both tissue sample panels were quantile
normalized together. All probes that have an overlap to a SNP
from dbSNP release 126 were masked out from the probeset
summarization procedure to reduce the influence of polymor-
phisms on probe hybridization to a SNP-containing target [27].
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Meta-probeset expression values were generated from the probeset
expression summaries.
Genotyping of samples
Genotyping was performed using the Illumina HapMap 550 k
Duo chip (Illumina Inc, San Diego, CA) according to protocols
provided by the manufacturer. The total number of SNPs
included on the chip is 561,303. Two individuals with low
genotyping rate were excluded (array call rate,98%), as were
90401 SNPs with low frequency (minor allele frequency,5%),
high rates of missing data (SNP call rate,90%), and showing
significant deviation from Hardy-Weinberg equilibrium (P,0.05),
leaving 58 samples for the study.
Transcriptomic Association Analysis
Probeset (exon) and meta-probeset (gene) expression levels were
examined for association with flanking SNPs. For each of the
274,097 core probesets and 17,749 meta-probesets, we tested for
association of the expression levels to SNPs within a 250 Kb
region flanking either side of the gene containing the probeset or
meta-probeset, using a linear regression model implemented in the
PLINK software package [28]. Gender, age, batch effects, and
eigen values for the 1st axis from the Eigenstrat analysis were used
as covariates in the regression model. Raw P-values were obtained
from the regression using the standard asymptotic t-statistic.
Networks Analysis
To visualize whole genome expression data in the context of
biological networks, we created meta-probeset lists based on
expression cutoffs and meta-probeset or probeset lists from top-
ranked SNP associations in one or both cell types, which were then
analyzed with the Ingenuity Pathways Analysis (IPA) system
(Ingenuity Systems, www.ingenuity.com). Datasets containing the
meta-probeset or probeset IDs and their corresponding expression
values or minimal P-values were uploaded in the application and
were mapped to its corresponding gene object in the Ingenuity
Pathways Knowledge system. These genes were overlaid onto a
global molecular network developed from the Ingenuity Pathways
Knowledge Base. IPA datasets for all species, all tissues & cell lines,
and all data sources were used in the analysis with default settings.
Networks of these genes were then algorithmically generated on
the basis of their connectivity.
The functional analysis identified the biological functions that
were most significant to the data set. Only genes that met the cutoff
and were associated with biological functions in Ingenuity Pathways
Knowledge were considered for analysis. Fisher’s exact test was used
to calculate a P-value determining the probability that each
biological function assigned to the data set is due to chance only.
Canonical pathways analysis identified the networks that were
the most significant to the data set. Genes that met the cutoff in the
functional analyses and were associated with a canonical pathway
in the Ingenuity Pathways Knowledge Base were considered for
the analysis. The significance of the association between the data
set and the canonical pathway was measured in two ways: 1) a
ratio of the number of genes from the data set that map to the
pathway divided by the total number of genes that map to the
canonical pathway was displayed and 2) Fisher’s exact test was
used to calculate a P-value determining the probability that the
association between the genes in the data set and the canonical
pathway is explained by chance alone.
Validation of transcript isoform changes by RT-PCR
First strand cDNA was synthesized using random hexamers
(Invitrogen, Burlington, Canada) and Superscript II reverse
transcriptase (Invitrogen, Burlington, Canada). Candidate probe-
sets showing an association were validated in two ways, depending
on their location within the gene. For all probesets located within
coding exons and possessing flanking exons in all known RefSeq
isoforms, we designed locus specific primers within the adjacent
flanking exons. Approximately 20 ng of total cDNA was then
amplified by PCR using Hot Start Taq Polymerase (Qiagen,
Mississauga, Canada) with an activation step at 95uC (15 min)
followed by 35 cycles at 95uC (30 s), 58uC (30 s) and 72uC (40 s)
and a final extension step at 72uC (5 min). Amplicons were
visualized by electrophoresis on a 2.5% agarose gel.
For probesets located within the 59 or 39 untranslated regions or
within exons that did not have both flanking exons (i.e. first or last
exon of a multi-exon gene), we designed a set of primers to amplify
the differentially expressed candidate probeset itself. For compar-
ison, additional primer pairs were designed to amplify products
corresponding to the adjacent probesets and which were not
significantly associated with the same SNP. Total expression
measurements were carried out using real-time PCR with Power
SYBR Green PCR Master Mix (Applied Biosystems, Foster City,
CA, USA) following the manufacturer’s instruction on an ABI
7900HT (Applied Biosystems, Foster City, CA, USA) instrument.
The reaction was set up in 10 ml final volume applying the following
conditions: 8 ng of total cDNA and 0.32 mM of gene-specific
primers; cycling: 95uC (15 min) and 95uC (20 s), 58uC (30 s), 72uC
(45 s) for 40 cycles. Relative quantification of each amplicon was
evaluated on RNA from at least 3–4 samples corresponding to each
of the three possible genotypes for the associated SNP. For each
amplicon including the human 18S used as endogenous control, a
standard curve was established using a dilution series of a mix of
cDNA samples with known total cDNA concentration in order to
determine if the amplification reactions had the same PCR
efficiency. Expression levels of target and 18S were evaluated using
the comparative Ct (cycle threshold) method where three technical
replicates were averaged and normalized based on 18S real-time
data from the same samples. The quantitative data was used in
regression analyses with the same SNP identified in the original
association to confirm the significance, using a P-value threshold of
0.05/N where N is the number of candidate genes tested using this
method. The regression trend had to be in the same direction as in
the original association. Quantitative RT-PCR of the control
probesets showing no association with the SNP should also be non-
significant at this threshold.
59 Rapid Amplification of cDNA Ends (RACE)
The 59 Rapid Amplification of cDNA Ends (RACE) System
(Invitrogen, Burlington, Canada) was used to identify the unknown
sequences at the 59 end of the novel FAM118A transcript according
to manufacturer’s guidelines. First strand cDNA was synthesized
from 1 mg of total RNA using a gene-specific primer and
SuperScriptII reverse transcriptase (Invitrogen, Burlington, Ca-
nada). The original mRNA template was removed by RNase H
treatment and the first strand cDNA product was purified on
columns provided with the system to remove unincorporated
dNTPs and primers. A homopolymeric tail was added to the 3’ end
of the cDNA using TdT and dCTP, and the fragment was amplified
by PCR using a nested, gene-specific and a deoxyinosine-containing
anchor primer provided with the system using Hot Start Taq
Polymerase (Qiagen, Mississauga, Canada) with an activation step
at 95uC (15 min) followed by 35 cycles at 95uC (30 s), 58uC (30 s)
and 72uC (3 min) and a final extension step at 72uC (10 min). The
PCR product was diluted 506in TE buffer and further amplified
using a nested gene-specific primer and an Abridged Universal
Amplification Primer provided with the system using Hot Start Taq
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Polymerase with an activation step at 95uC (15 min) followed by 30
cycles at 95uC (30 s), 58uC (30 s) and 72uC (3 min) and a final
extension step at 72uC (10 min). Amplicons were visualized by
electrophoresis on a 1% agarose gel and sequenced using ABI Big
Dye chemistry and capillary electrophoresis on an ABI 3730
sequencer (Applied Biosystems, Foster City, CA).
Fine-mapping of FAM118A
The top hit from the comparison of probeset associations with
known bone-related GWAS loci was further fine-mapped where
selected HapMap SNPs in the FAM118A (Table S7) gene
(chr22:44,083,527–44,118,573) were genotyped using the Seque-
nom MassARRAY iPLEX Gold technology (Sequenom Inc.,
Newton, MA). Briefly, around 40 SNPs were multiplexed per
individual reaction and a single base primer extension step was
performed. The primer extension products were then analyzed
using MALDI TOF MS.
Re-sequencing and genotyping of non-HapMap SNPs
To identify all genetic polymorphisms potentially responsible for
the differences in gene expression, approximately 6 kb of the
candidate region (chr22:44,097,900–44,104,182) in the FAM118A
gene was re-sequenced using standard Sanger sequencing using
ABI Big Dye chemistry and capillary electrophoresis on an ABI
3730 sequencer (Applied Biosystems, Foster City, CA). In total,
eight individuals were selected based on the candidate SNPs (four
samples from each homozygous genotype group of the top SNPs)
and overlapped regions were amplified and sequenced using
primers listed in Table S8. Non-HapMap SNPs and/or novel
SNPs that were homozygous in all eight samples were genotyped
in the complete panel of HObs using Sanger sequencing.
Primer design
Primers were designed using the Primer3 v. 0.4.0 software
(http://frodo.wi.mit.edu/) and all primer sequences can be found
in Table S8.
Clinical cohorts
The effect of the identified SNPs on clinical bone phenotypes
was tested in two population-based studies involving Caucasian
male subjects of European origin: The MrOs Cohort, Sweden
(MrOs), and The Rotterdam Study (RS), Netherlands.
The MrOs study is a multi-centre prospective fracture
epidemiology investigation involving elderly men from different
sites around the world including the US, Hong Kong and Sweden.
The Swedish part consists of 3014 men aged between 69–81 years
that were randomly selected from the population registry [29].
Bone mineral density (BMD) of the lumbar spine (L1-L4), and
femoral neck was measured using dual energy X-ray absorptiom-
etry (DXA) using either a Hologic QDR 4500/A-Delphi (QDR
4500 W, Hologic, Inc.) or a Lunar Prodigy DXA (GE Lunar
Corp.). To allow pooling of DXA measurements performed with
different equipments, standardized BMD (sBMD) was calculated
using previously reported algorithms [30,31]. DNA samples from
2880 individuals were included in the study and the rs104664 SNP
was genotyped using the Sequenom MassARRAY iPLEX Gold
technology (Sequenom Inc., Newton, MA) that includes a single
base primer extension and MALDI TOF Mass Spectrometry.
The RS is a prospective population-based cohort study of
chronic disabling conditions in Dutch elderly individuals age 55
years and over [32,33]. BMD measurement at the lumbar spine
(L1-L4) and the femoral neck was performed by DXA follow-
ing standard manufacturer protocols (GE-Lunar Corporation,
Madison, WI or Hologic Incorporated, Bedford, MA). The
rs104664 SNP was obtained from microarray genotyping
performed in the whole original RS cohort using the Infinium II
HumanHap550K Genotyping BeadChip version 3 (Illumina) as
part of a large population-based project on genetics of complex
traits and diseases. Genotyping procedures were followed
according to Illumina manufacturer’s protocols. All participants
of the original RS cohort with proper quality DNA samples
(n = 6449) were genotyped with the array. Intensity files were
analyzed using the Bead Studio Genotyping Module software
v.3.1.14. A no-call threshold of 0.15 was applied to a custom-
generated cluster file derived from the Illumina-provided cluster
file (based on the cluster definitions applied to the HapMap CEPH
cohort). In the custom- cluster file, 2308 SNPs with Genecall
scores,0.90 were visually checked by two observers and manually
re-clustered or zeroed accordingly. Poorly performing samples
with low call rate and 10th percentile Genecall scores were
excluded prior to calling genotypes. Any samples with a call rate
below 97.5% (n= 209), excess autosomal heterozygosity.0.336
,FDR,0.1% (n= 21), mismatch between called and phenotypic
gender (n = 36), or if there were outliers identified by the IBS
clustering analysis deviating.3 standard deviations away from the
population mean (n= 102), or with IBS probabilities.97%
(n= 129) were excluded from the analysis; in total, 5974 samples
were analyzed. Of the 5974 individuals with a mean age of 69.4
(SD 9.1) years, 3547 (59.4%) were women.
All statistical analyses for the clinical associations in the MrOs
Study were performed using SAS 9.1 software (SAS institute Inc.).
A general linear model was used to study the effect of genotype on
phenotypes (lumbar spine and femoral neck BMD) adjusted for
age, weight, height and study center. The RS used age- and
weight-adjusted standardized residuals of both lumbar spine and
femoral neck BMD analyzed under an additive (per allele) genetic
model using PLINK 1.05
Supporting Information
Figure S1 Principal Component Analysis (PCA) of lymphoblast
and osteoblast samples. (A) A two-dimensional plot of the meta-
probeset data showing the separation of the LCLs (n= 171) and
HObs (n= 58). The percentage of variance attributed to principal
components one and two are shown on the X and Y-axes,
respectively. (B) A two-dimensional plot of Eigenstrat analysis of
the HObs meta-probeset data.
Found at: doi:10.1371/journal.pgen.1000608.s001 (0.67 MB PDF)
Figure S2 False Discovery Rate (FDR) analysis of associations.
FDR discovery analysis of association P-values. In order of
decreasing significance, consecutive windows of 100 associations
are extracted in one tissue. The corresponding P-values in the 2nd
comparative tissue are extracted and FDR is performed on this 2nd
set of P-values. The number of hits falling below the FDR cutoff
(0.05 level = red, 0.01 level = blue) is plotted for each of these
windows. This was done for meta-probesets in (A) HObs and (B)
LCLs, as well as probesets in (C) HObs and (D) LCLs.
Found at: doi:10.1371/journal.pgen.1000608.s002 (0.32 MB PDF)
Figure S3 Tissue-independent cis-associations of FAM118A
transcript expression. (A) The top significant SNPs associated
with FAM118A transcript expression in different populations and
tissues. P-values of association for probeset 3948567 expression
scores and SNP genotypes from (B) HOb, (C) HapMap CEU
LCL, (D) HapMap YRI LCL (Zhang et al, AJHG 2008), (E)
PBMCs (Heinzen et al., PLoS Biology 2008), and (F) Cortical
brain tissue (Heinzen et al., PLoS Biology 2008) are shown as
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vertical bars and represented as -log10PV. (G) RefSeq transcripts
in the FAM118A and flanking regions. (H) YRI and (I) CEU
linkage disequilibrium blocks.
Found at: doi:10.1371/journal.pgen.1000608.s003 (1.30 MB PDF)
Figure S4 Association of the top significant SNP with all
FAM118A probesets in different populations and tissues. (A) All
probesets corresponding to the newly identified FAM118A
transcript variant. P-values of association for linear regression of
the FAM118A probesets in different samples and genotypes of (B)
rs104664 in HObs, (C) rs738177 in HapMap CEU LCLs, (D)
rs742014 in HapMap YRI LCLs, (E) rs104664 in PBMCs, and (F)
Cortical brain tissue are shown as vertical bars and represented as
-log10PV. (G) Two different RefSeq transcripts of FAM118A,
NM_001104595 and NM_017911.
Found at: doi:10.1371/journal.pgen.1000608.s004 (0.28 MB PDF)
Table S1 HOb panel information.
Found at: doi:10.1371/journal.pgen.1000608.s005 (0.02 MB
XLS)
Table S2 Mean expression scores and fold change for HOb and
LCL expressed genes.
Found at: doi:10.1371/journal.pgen.1000608.s006 (1.21 MB
XLS)
Table S3 HOb and LCL expressed genes (canonical pathways).
Found at: doi:10.1371/journal.pgen.1000608.s007 (0.02 MB
XLS)
Table S4 Canonical pathways for tissue-specific expressed
genes.
Found at: doi:10.1371/journal.pgen.1000608.s008 (0.02 MB
XLS)
Table S5 Canonical pathways of tissue-specific upregulated
genes (expressed in both HObs and LCLs).
Found at: doi:10.1371/journal.pgen.1000608.s009 (0.02 MB
XLS)
Table S6 Canonical pathways of tissue-specific genetic associa-
tions at probeset level.
Found at: doi:10.1371/journal.pgen.1000608.s010 (0.02 MB
XLS)
Table S7 Fine-mapped SNP of the FAM118A locus.
Found at: doi:10.1371/journal.pgen.1000608.s011 (0.02 MB
XLS)
Table S8 Primer sequences.
Found at: doi:10.1371/journal.pgen.1000608.s012 (0.03 MB
XLS)
Table S9 Probeset associations with known bone-related GWAS
loci.
Found at: doi:10.1371/journal.pgen.1000608.s013 (0.05 MB
XLS)
Table S10 Association of SNPs in the FAM118A gene with
probeset expression.
Found at: doi:10.1371/journal.pgen.1000608.s014 (0.14 MB
XLS)
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